InnoCan Pharma Corporation
INNPF
$0.132
-$0.0031-2.30%
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -0.23% | 27.72% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -0.23% | 27.72% | |||
| Cost of Revenue | 30.80% | -15.78% | |||
| Gross Profit | -2.74% | 33.28% | |||
| SG&A Expenses | 0.13% | 3.71% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.97% | 1.65% | |||
| Operating Income | -33.83% | 143.89% | |||
| Income Before Tax | -51.05% | 217.54% | |||
| Income Tax Expenses | -12.55% | 104.27% | |||
| Earnings from Continuing Operations | -70.29% | 165.75% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 7.27% | -97.76% | |||
| Net Income | -186.05% | 119.07% | |||
| EBIT | -33.83% | 143.89% | |||
| EBITDA | -33.39% | 145.09% | |||
| EPS Basic | -183.33% | 118.46% | |||
| Normalized Basic EPS | -150.00% | 125.00% | |||
| EPS Diluted | -200.00% | 115.38% | |||
| Normalized Diluted EPS | -150.00% | 125.00% | |||
| Average Basic Shares Outstanding | 0.35% | 4.02% | |||
| Average Diluted Shares Outstanding | 0.35% | 4.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
